Form 8-K · Current Report · Filed 2025-10-01
Halozyme Therapeutics Announces Acquisition of Elektrofi to Expand Drug Delivery Capabilities
Halozyme Therapeutics, Inc. has announced its acquisition of Elektrofi, Inc., a biopharmaceutical company specializing in ultra-high concentration microparticle technology for biologics. The acquisition, which includes an upfront payment of $750 million and up to three $50 million milestone payments contingent on product regulatory approvals, is expected to expand Halozyme's drug delivery technology offerings and strengthen its long-term revenue growth into the 2040s. The transaction is anticipated to be less than 5% dilutive to Non-GAAP diluted EPS over the medium-term, excluding potential milestone payments. Halozyme remains committed to its 2025 financial guidance, with expected total revenue growth of 26% to 33% over 2024, driven by increases in royalty revenue.
- Filer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Accession
- 0001193125-25-225853
- CIK
- 0001159036
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Regulation FD Disclosure
Financial Statements and Exhibits
Market reaction
Close before filing
$73.34
Next session
-2.2%
Since filing
+50.3%
Latest close
$110.24
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from HALO reporting the same item, with the next session's move:
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Never miss another HALO filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.